我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

阿托伐他汀对扩张型心肌病患者肌钙蛋白I水平及预后的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2011年第5期
页码:
633-635
栏目:
临床研究
出版日期:
2011-10-25

文章信息/Info

Title:
Effects of atorvastatin on levels of serum cardiac troponin I and prognosis in patients with dilated cardiomyopathy
作者:
郭寿贵; 邓节喜; 阮发晖; 窦 燕
解放军第175医院心内科，福建 漳州 363000
Author(s):
GUO Shou-gui;  DENG Jie-xi;  RUAN Fa-hui;  DOU Yan
Department of Cardiology, PLA 175 Hospital, Zhangzhou 363000, Fujian, China
关键词:
阿托伐他汀; 心肌病; 扩张型; 肌钙蛋白I; 预后
Keywords:
atorvastatin;  dilated cardiomyopathy;  cardiac troponin I;  prognosis
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
目的:研究阿托伐他汀对扩张型心肌病（DCM）患者血清肌钙蛋白I(cTnI)水平及预后的影响。方法： 对72例DCM住院患者随机分成2组：他汀组及非他汀组（各36例），治疗前两组在性别、年龄、病程、NYHA心功能分级、左室射血分数（LVEF）、左室舒张末期内径（LVEDD）、心律失常等方面无显著差异，两组均常规抗心力衰竭等治疗，而他汀组加用阿托伐他汀（立普妥）10 mg/d，分别随访1年，观察治疗前、治疗3个月后两组的cTnI水平变化情况，评估随访1年内主要不良心血管事件（心血管死亡、心脏骤停复苏及卒中）风险及心力衰竭再住院率。结果： 他汀组治疗3个月后cTnI水平较非他汀组有所下降，但差异无统计学意义；随访期间非他汀组主要心血管不良事件发生16例次（48%），他汀组14例次（42%）；非他汀组因心衰再住院16例次（48%），他汀组11例次（33%），P>0.05。结论： 低剂量阿托伐他汀治疗对DCM患者的cTnI水平及预后无明显影响，对心衰住院率亦无明显降低作用。
Abstract:
AIM:To study the effects of atorvastain on serum cardiac troponin I (cTnI) levels and the prognosis in patients with dilated cardiomyopathy (DCM). METHODS: Seventy two consecutive patients hospitalized for DCM were divided randomly into two groups: statin group and no-statin group. There were no significant differences between groups according to gender, age, history of DCM, NYHA cardiac functional grading, left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD) and cardiac arrhythmia. Patients of both groups were treated with conventional medication for anti-heart failure strategies, whereas patients in statin group were additionally given atorvastatin (10 mg daily). Both groups were followed up for ~1 year. Changes of cTnI levels were determined before and after 3 months treatment. Risk of major adverse cardiovascular events (MACE) was evaluated including cardiovascular mortality, resuscitated cardiac arrest and stroke, and rates of rehospitalization for worsening heart failure (HF) during 1-year follow-up. RESULTS: Lower levels of the cTnI were observed in the statin group compared with those in the no-statin group after 3 months treatment but no significant difference was seen. There were 30 episodes of MACE during follow-up, 16 in no-statin group and 14 in statin group (P>0.05) and a nonsignificant trend toward lower readmission rate for worsening HF in statin group (33% vs. 48%, P>0.05). CONCLUSION: Low-dose atorvastatin therapy has no significant beneficial effect on the prognosis in DCM patients and did not significantly reduce the rate of rehospitalization for worsening HF.

参考文献/References

[1]Horwich TB,Patel J,MacLellan WR,et al.Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure[J]. Circulation,2003,108(7): 833-838.

[2]Guerra S,Leri A,Wang X,et al.Myocyte death in the failing human heart is gender dependent[J].Circ Res,1999,85（9）:856-866.

[3] Domanski M,Coady S,Fleg J,et al.Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial BEST］)[J]Am J Cardiol,2007, 99(10):1448-1450.

[4]Go AS,Lee WY,Yang J,et al.Statin therapy and risks for death and hospitalization in chronic heart failure[J].JAMA,2006,296(17):2105-2111.

[5]Goldberger JJ,Subacius H,Schaechter A,et al.Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy[J].J Am Coll Cardiol,2006,48(6):1228-33.

[6]Kjekshus J,Apetrei E,Barrios V,et al.Rosuvastatin in older patients with systolic heart failure[J].N Engl J Med,2007,357(22):2248-2261.

[7]Gissi-HF Investigators,Tavazzi L,Maggioni AP,et al.Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial[J].Lancet,2008,372(9645):1231-1239.

[8]Lipinski MJ,Cauthen CA,Biondi-Zoccai GG,et al.Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure[J].Am J Cardiol,2009,104(12):1708-1716.

备注/Memo

备注/Memo:
收稿日期：2010-10-27.作者简介：郭寿贵，主治医师，硕士Email:guojun175@yahoo.com.cn
更新日期/Last Update: 2011-11-03